Inventiva (NASDAQ:IVA) Posts Earnings Results, Misses Expectations By $0.08 EPS

Inventiva (NASDAQ:IVA) announced its quarterly earnings data on Monday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08), reports. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $2.88 million.

Here are the key takeaways from Inventiva’s conference call:

• NATiV3 Phase III remains on track for top-line MASH results in Q4 2026 after the final patient completed the 72-week visit; the main cohort includes 1,009 patients with biopsy-confirmed F2/F3 MASH.
• If results are positive, Inventiva plans to pursue an FDA NDA filing in the first half of 2027 and a potential U.S. commercial launch in 2028, while also preparing a confirmatory outcomes trial in advanced compensated liver disease.
• Management highlighted Phase IIb results showing placebo-adjusted improvements in fibrosis, MASH resolution and the composite endpoint, supporting its view that once-daily oral lanifibranor could address both hepatic and metabolic drivers of disease.
• The company expects to evaluate whether both doses should be commercialized, depending on Phase III efficacy and tolerability; it has not disclosed the scope of the Q4 data release or subgroup results for patients using GLP-1 or SGLT2 therapies.
• Lanifibranor’s known PPAR-gamma-related effects include weight gain, edema and hemoglobin decline, although management characterized them as generally mild to moderate and potentially manageable with therapies such as SGLT2 inhibitors.
• Following its June financing actions, Inventiva reported €233.9 million in cash and short-term deposits and a cash runway through Q2 2027, potentially extending to early 2028 if additional financing tranches and warrants are realized.

Inventiva Trading Down 6.8%

Shares of Inventiva stock opened at $3.29 on Wednesday. The firm’s 50-day moving average is $4.38 and its 200 day moving average is $4.71. Inventiva has a 1 year low of $3.11 and a 1 year high of $7.98.

Wall Street Analysts Forecast Growth

IVA has been the subject of a number of analyst reports. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Cantor Fitzgerald initiated coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating for the company. Guggenheim lifted their price objective on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Inventiva has a consensus rating of “Buy” and an average price target of $15.14.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.